Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Tongue Neoplasms 1Salivary Gland Neoplasms 1Rectal Neoplasms 1Parathyroid Neoplasms 1Oropharyngeal Neoplasms 1Neovascularization, Pathologic 1Nasopharyngeal Neoplasms 1Mouth Neoplasms 1Lung Neoplasms 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Hyperparathyroidism, Primary 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Sunitinib 145Nivolumab 144pembrolizumab 132Sorafenib 84Bevacizumab 77Everolimus 74cabozantinib 71pazopanib 65Axitinib 65Ipilimumab 62aldesleukin 52Magnetic Resonance Spectroscopy 45Cyclophosphamide 40Interleukin-2 38lenvatinib 37Specimen Handling 36Radiosurgery 36Interferon-alpha 32atezolizumab 30temsirolimus 27belzutifan 24Gemcitabine 23fludarabine phosphate 22avelumab 22Radiotherapy 19Interferon alpha-2 19Biopsy 18fludarabine 17durvalumab 17Nephrectomy 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × Rubidium-82 × Clear all
NCT07346404 2026-01-16

RUBIKID

Assistance Publique - Hôpitaux de Paris

Phase 2 Not yet recruiting
50 enrolled
Genitourinary

Carcinoma, Renal Cell, Neovascularization, Pathologic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡